CO6241137A2 - Antagonistas ciclicos de peptido cxcr4 - Google Patents
Antagonistas ciclicos de peptido cxcr4Info
- Publication number
- CO6241137A2 CO6241137A2 CO09135750A CO09135750A CO6241137A2 CO 6241137 A2 CO6241137 A2 CO 6241137A2 CO 09135750 A CO09135750 A CO 09135750A CO 09135750 A CO09135750 A CO 09135750A CO 6241137 A2 CO6241137 A2 CO 6241137A2
- Authority
- CO
- Colombia
- Prior art keywords
- glu
- group
- asp
- dglu
- side chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Un péptido ciclizado por lactamas de fórmula I:R1 - ciclo[X1 - Tyr - X3 - DArg - 2Nal - Gly - X7] - X8 - X9 -caracterizado porque:a) la lactama se forma por un enlace amida entre el grupo amino de cadena lateral de X1 y el grupo carboxilo de cadena lateral de X7, en donde X1 y X7 son, respectivame, un par seleccionado del grupo que consiste de (D/L)Agl/Glu, Dab/Glu, y Dap/Glu, y R1 es Ac o n-hexanoilo; o b) la lactama se forma por un enlace amida entre el grupo carboxilo de cadena lateral de X1 y el grupo amino de grupo cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Asp/(D/L)Agl, Asp/Dab, Asp/Dap, Glu/(D/L)Agl, Glu/Dab, Glu/Dap, Glu/DDap, y Glu/Lys, y R1 es Ac o Bz, o en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de succinilo/ (D/L)Agl, succinilo/Dab, succinilo/DaP, succinilo/Lys, y succinilo/Orn, y R1 está ausente; o c) la lactama se forma por un enlace amida entre el grupo a-amino de X1 y el grupo carboxilo de cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Ala/Glu, Ala/DGlu, DAla/Glu, DAla/DGlu, Dap(Ac)/Glu, Gly/Asp, Gly/Glu, Gly/DGlu, Leu/Glu, Leu/DGlu, Lys/DGlu, Lys(Ac)/Glu, 2Nal/Glu, Phe/Glu, Phe/DGlu, DPhe/Glu, y DPhe/DGlu, y R1 está ausente; o d) la lactama se forma por un enlace amida entre un grupo amino no a, sin cadena lateral de X1 y el grupo carboxilo de cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de ß-Ala/Asp, -Ala/Glu, 5-amino-valerilo/Asp, 5- aminovalerilo/Glu, 4-AMB/Glu, 4-AMPA/Asp, y 4-AMPA/Glu, y R1 está ausente; o e) la lantana se forma por un enlace amida entre el grupo a-amino de X2 y el grupo carboxilo de cadena lateral de X7, en donde X2 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Tyr/Asp, Tyr/Glu, y Tyr/DGlu, y R1 y X1 están cada uno ausentes; R1 es un sustituyente sobre el grupo a-amino de X1 cuando X1 contiene un grupo a-amino y el grupo a-amino no es un constituyente del enlace amida de la lactama, seleccionado del grupo que consiste de Ac, Bz, y n-hexanoilo, o está ausente, en donde X1 es seleccionado del grupo que consiste de (D/L)Agl, Asp, Dab, Dap, y Glu;X1 es seleccionado del grupo que consiste de (D/L)Agl, Ala, -ß-Ala, DAla, 5-aminovalerilo, 4-AMB, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94080207P | 2007-05-30 | 2007-05-30 | |
| US94099607P | 2007-05-31 | 2007-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6241137A2 true CO6241137A2 (es) | 2011-01-20 |
Family
ID=39831600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09135750A CO6241137A2 (es) | 2007-05-30 | 2009-11-27 | Antagonistas ciclicos de peptido cxcr4 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7691813B2 (es) |
| EP (2) | EP2377579A1 (es) |
| JP (1) | JP5358564B2 (es) |
| KR (2) | KR101319740B1 (es) |
| CN (1) | CN101678213B (es) |
| AR (1) | AR066648A1 (es) |
| AT (1) | ATE516853T1 (es) |
| AU (1) | AU2008260326B2 (es) |
| BR (1) | BRPI0812134A2 (es) |
| CA (1) | CA2688574C (es) |
| CL (1) | CL2008001467A1 (es) |
| CO (1) | CO6241137A2 (es) |
| CR (1) | CR11105A (es) |
| CY (1) | CY1111815T1 (es) |
| DK (1) | DK2160221T3 (es) |
| DO (1) | DOP2009000270A (es) |
| EA (1) | EA017716B1 (es) |
| GT (1) | GT200900304A (es) |
| HK (1) | HK1141474A1 (es) |
| HR (1) | HRP20110551T1 (es) |
| IL (1) | IL201685A (es) |
| JO (1) | JO2776B1 (es) |
| MA (1) | MA31666B1 (es) |
| MX (1) | MX2009012952A (es) |
| MY (1) | MY149432A (es) |
| NZ (1) | NZ580849A (es) |
| PE (1) | PE20090299A1 (es) |
| PL (1) | PL2160221T3 (es) |
| PT (1) | PT2160221E (es) |
| TN (1) | TN2009000496A1 (es) |
| TW (1) | TWI423987B (es) |
| WO (1) | WO2008150689A1 (es) |
| ZA (1) | ZA200908345B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2942798B1 (fr) * | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| IT1397901B1 (it) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| WO2012118124A1 (ja) * | 2011-03-01 | 2012-09-07 | 国立大学法人京都大学 | 新規ケモカイン受容体拮抗剤 |
| MX343205B (es) * | 2011-06-07 | 2016-10-28 | Polyphor Ag | Peptidomiméticos de horquilla beta como antagonistas de cxc4. |
| WO2013044500A1 (zh) * | 2011-09-30 | 2013-04-04 | Cheng Yun | 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP2979991A1 (en) | 2014-07-31 | 2016-02-03 | Greif International Holding BV. | Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat. |
| EP3613435A1 (en) | 2015-01-28 | 2020-02-26 | Universite De Bordeaux | Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| EP3509612A4 (en) * | 2016-09-06 | 2021-07-21 | Mainline Biosciences | CXCR4 ANTAGONISTS AND METHOD OF USE |
| CN106841624B (zh) * | 2017-01-26 | 2019-02-22 | 庄磊靓 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
| KR20230145543A (ko) * | 2017-09-05 | 2023-10-17 | 메인라인 바이오사이언스 | 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법 |
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| WO2019126796A1 (en) * | 2017-12-21 | 2019-06-27 | Mainline Biosciences Llc | Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same |
| JP2021165234A (ja) * | 2018-07-03 | 2021-10-14 | 富士フイルム富山化学株式会社 | Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体 |
| EA202190755A1 (ru) | 2018-09-12 | 2021-06-11 | Технише Универзитет Мюнхен | Агенты для терапии и диагностики рака |
| EP3849997B1 (en) | 2018-09-12 | 2024-05-01 | Technische Universität München | Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity |
| CN114364690A (zh) * | 2019-04-18 | 2022-04-15 | 省卫生服务机构 | 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物 |
| CN115003684A (zh) * | 2020-01-26 | 2022-09-02 | 主线生物科学有限公司 | 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法 |
| TW202235429A (zh) * | 2020-12-25 | 2022-09-16 | 日商中外製藥股份有限公司 | 含ｎ－置換－胺基酸殘基之胜肽化合物的製備方法 |
| EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
| WO2023201435A1 (en) * | 2022-04-20 | 2023-10-26 | Provincial Health Services Authority | Cxcr4-targeting compounds, and methods of making and using the same |
| CN115060901A (zh) * | 2022-06-21 | 2022-09-16 | 中国医学科学院基础医学研究所 | 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4391123B2 (ja) * | 2002-10-24 | 2009-12-24 | 株式会社オーファンリンク | 新規ｃｘｃｒ４アンタゴニスト |
| CA2643744A1 (en) | 2006-02-27 | 2007-08-30 | Technische Universitaet Muenchen | Cancer imaging and treatment |
-
2008
- 2008-05-20 KR KR1020117026680A patent/KR101319740B1/ko not_active IP Right Cessation
- 2008-05-20 US US12/123,574 patent/US7691813B2/en not_active Ceased
- 2008-05-20 KR KR1020097024829A patent/KR101169846B1/ko not_active IP Right Cessation
- 2008-05-20 PL PL08769524T patent/PL2160221T3/pl unknown
- 2008-05-20 PE PE2008000868A patent/PE20090299A1/es not_active Application Discontinuation
- 2008-05-20 AU AU2008260326A patent/AU2008260326B2/en not_active Ceased
- 2008-05-20 CA CA2688574A patent/CA2688574C/en not_active Expired - Fee Related
- 2008-05-20 WO PCT/US2008/064177 patent/WO2008150689A1/en active Application Filing
- 2008-05-20 MY MYPI20095053A patent/MY149432A/en unknown
- 2008-05-20 CL CL2008001467A patent/CL2008001467A1/es unknown
- 2008-05-20 AT AT08769524T patent/ATE516853T1/de active
- 2008-05-20 EA EA200971129A patent/EA017716B1/ru not_active IP Right Cessation
- 2008-05-20 AR ARP080102137A patent/AR066648A1/es unknown
- 2008-05-20 NZ NZ580849A patent/NZ580849A/en not_active IP Right Cessation
- 2008-05-20 BR BRPI0812134-6A2A patent/BRPI0812134A2/pt not_active IP Right Cessation
- 2008-05-20 MX MX2009012952A patent/MX2009012952A/es active IP Right Grant
- 2008-05-20 PT PT08769524T patent/PT2160221E/pt unknown
- 2008-05-20 TW TW097118554A patent/TWI423987B/zh not_active IP Right Cessation
- 2008-05-20 EP EP11172401A patent/EP2377579A1/en not_active Withdrawn
- 2008-05-20 JP JP2010510418A patent/JP5358564B2/ja not_active Expired - Fee Related
- 2008-05-20 DK DK08769524.3T patent/DK2160221T3/da active
- 2008-05-20 EP EP08769524A patent/EP2160221B1/en active Active
- 2008-05-20 CN CN2008800178577A patent/CN101678213B/zh not_active Expired - Fee Related
- 2008-05-20 JO JO2008229A patent/JO2776B1/en active
-
2009
- 2009-10-22 IL IL201685A patent/IL201685A/en not_active IP Right Cessation
- 2009-11-10 CR CR11105A patent/CR11105A/es not_active Application Discontinuation
- 2009-11-25 ZA ZA2009/08345A patent/ZA200908345B/en unknown
- 2009-11-26 GT GT200900304A patent/GT200900304A/es unknown
- 2009-11-26 TN TNP2009000496A patent/TN2009000496A1/fr unknown
- 2009-11-27 DO DO2009000270A patent/DOP2009000270A/es unknown
- 2009-11-27 CO CO09135750A patent/CO6241137A2/es active IP Right Grant
- 2009-12-21 MA MA32439A patent/MA31666B1/fr unknown
-
2010
- 2010-01-25 US US12/692,788 patent/US20100130409A1/en not_active Abandoned
- 2010-08-20 HK HK10107961.8A patent/HK1141474A1/xx not_active IP Right Cessation
- 2010-09-10 US US12/807,694 patent/USRE42274E1/en not_active Expired - Fee Related
-
2011
- 2011-07-25 HR HR20110551T patent/HRP20110551T1/hr unknown
- 2011-09-07 CY CY20111100861T patent/CY1111815T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6241137A2 (es) | Antagonistas ciclicos de peptido cxcr4 | |
| NZ601175A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| JP2010529957A5 (es) | ||
| NO20084008L (no) | HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| DE602005008996D1 (de) | Radiofluorierte peptide | |
| NZ607892A (en) | Tfpi inhibitors and methods of use | |
| CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| WO2008093058A3 (en) | Peptides and their use | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| SG11201902818PA (en) | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation | |
| WO2002100885A3 (en) | A penta- or tetrapeptide binding to somatostatin receptors and the use of the same | |
| NZ601647A (en) | Variant hhip1 protein and methods and uses thereof | |
| Koizumi et al. | Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers | |
| DE60031422D1 (de) | Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors | |
| IN2014MN02080A (es) | ||
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |